Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | BRAF V600E CD274 pos |
Therapy | Pembrolizumab |
Indication/Tumor Type | lung adenocarcinoma |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
BRAF V600E CD274 pos | lung adenocarcinoma | predicted - sensitive | Pembrolizumab | Case Reports/Case Series | Actionable | In a clinical case study, a patient with CD274 (PD-L1)-positive (IHC = 90% of tumor cells) metastatic lung adenocarcinoma who progressed after an 18-month response to Tafinlar (dabrafenib) treatment based on the presence of BRAF V600E, was then treated with Keytruda (pembrolizumab) for two cycles, and achieved an early response and remained progression-free 7 months after initiating immunotherapy (PMID: 29142786). | 29142786 |
PubMed Id | Reference Title | Details |
---|---|---|
(29142786) | Extraordinary clinical benefit to sequential treatment with targeted therapy and immunotherapy of a BRAF V600E and PD-L1 positive metastatic lung adenocarcinoma. | Full reference... |